Feature interview: How to overcome a victim mindset
Newsflash. No one's life is perfect. But we've managed to turn everyday suffering into social currency and being a victim into a competitive sport says renowned psychologist Dr Scott Barry Kaufman. In the age of TikTok therapy, typical difficult feelings are treated like a diagnosis. Dr Kaufman says that while some adversity is real, it can be the start of the story not the end of it. His new book offers insights about taking personal responsibility and embracing the idea that our greatest challenges can result in our greatest victories. The book is called Rise Above: Overcome a Victim Mindset, Empower Yourself, and Realize Your Full Potential.
To embed this content on your own webpage, cut and paste the following:
See terms of use.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
2 days ago
- RNZ News
Experimental new drug results in up to 24pct weight loss, comes in a pill
By Deena Beasley , Reuters The full trial results were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Photo: 123rf Novo Nordisk on Friday (local time) said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24 percent of their weight as the Danish company readies for late-stage studies to start next year. The company said side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar to other recent weight loss drugs. The [ full trial results[ were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Novo's head of development Martin Holst Lange said the Phase 3 amycretin program starting in 2026 will run "for a couple of years" after which the regulatory review process could start. The company earlier this month said it planned to start late-stage trials of the drug in the first quarter of 2026 after previously announcing the early-stage trial results. Amycretin has a dual-mode action. Like Novo's popular weight-loss drug Wegovy, it mimics the gut hormone GLP-1, but also targets receptors for a hunger-suppressing pancreatic hormone called amylin. Trial results showed that 20-milligram weekly injections of the drug helped overweight or obese patients without diabetes lose 22 percent of their weight over 36 weeks, with a 60-mg dose resulting in 24.3 percent weight loss. In the Phase 1 study of once-daily oral amycretin, patients received increasing doses, ranging from 3 mg to a final dose of 100 mg. Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4 percent on average, while those taking the maximum dose lost 13.1 percent of their weight, the company said. Novo said the weight loss did not plateau, suggesting that longer treatment could lead to greater weight loss. In a Lancet commentary, researchers not involved in the amycretin studies said that "while additional weight loss is welcome and helpful, our evolving concept of obesity management has now shifted towards an emphasis on the reduction of the risks and burdens of cardiovascular disease and other comorbidities". Commentators Tricia Tan, professor of metabolic medicine and endocrinology at Imperial College London, and endocrinologist Dr Bernard Khoo, said studies directly comparing GLP-1 drugs like Novo's Ozempic to drugs like amycretin will be needed to definitively establish their added value and place in obesity management. - Reuters
RNZ News
5 days ago
- RNZ News
"Don't worry, this won't hurt"
Don't worry, this won't hurt. When has that ever turned out to be true? Parents may try to ease a child's anxiety about a medical procedure with a white lie. But lies that mislead children about their experiences are not white lies, says Allison Sweet Grant. She endured terrible pain as a child from surgery to correct one leg that was shorter than the other. In her debut novel for young adults, Grant explores themes of agency, trust, and betrayal through a 19-year-old character facing the same medical trauma she did and learning how to heal. The book is called I am the Cage.
RNZ News
6 days ago
- RNZ News
Feature Interview: Herman Pontzer
It may seem unfair that some people can eat anything without putting on weight, get by on just a few hours sleep and age ever so gracefully. It's just biology and the science of adaptation says Dr Herman Pontzer, a professor of evolutionary anthropology at Duke University. Dr Pontzer invites us to embrace human diversity and focus on how and why we differ as a way to better understand how our bodies work so we can all stay healthy. His new book is called Adaptable: How Your Unique Body Really Works and Why Our Biology Unites Us. He joins Jesse. To embed this content on your own webpage, cut and paste the following: See terms of use.
